Back to homepage

Respiratory

Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL* protocol

Authors: Teodoro Iturbe-Hernandez MD, Luis García de Guadiana Romualdo MD, Ignacio Gil Ortega MD, Antonio Martínez Francés MD, Olga Meca Birlanga MD, Juan José Cerezo-Manchado MD

In this review, the available information on the antithrombotic management of atrial fibrillation patients at discharge after COVID-19 infection is updated. In addition, a practical algorithm, considering renal and liver function, which facilitates the anticoagulation choice at discharge is presented.

More

Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance

Authors: Adam Kisling MD, Jason Jones MD, Caleb Hixson DO FCAP, David Hostler MD MPH FACP, Jordanna Hostler MD FACP

This article presents a case of ICEP in which mepolizumab was used as a steroid-sparing agent, resulting in improvement in markers of disease activity
and corticosteroid requirement.

More

Can vitamins and/or supplements provide hope against coronavirus?

Authors: Sarah M Michienzi PharmD, Melissa E Badowski PharmD

The goal of this narrative review is to evaluate current and ongoing clinical trials of vitamins and supplements, alone or in combination with each other or other therapies, for the treatment of COVID-19.

More

Pharmacological treatment of COVID-19: lights and shadows

Authors: Francesco Menzella MD, Mirella Biava Msc, Chiara Barbieri MD, Francesco Livrieri MD, Nicola Facciolongo MD

The aim of this review is to explore COVID-19 treatment options and describe the potential benefits or disadvantages of their use in severe cases.

More

Targeting inducible epigenetic reprogramming pathways in chronic airway remodeling

Authors: Allan R Brasier MD, Istvan Boldogh DM&B, PhD

This article reviews recent systems-level studies that provide fundamental new insights into how repetitive activation of innate signaling pathways produce epigenetic ‘training’ to induce adaptive epithelial responses and presents studies demonstrating efficacy of these in reducing airway inflammation in preclinical models

More